Patents by Inventor Jinghe Huang
Jinghe Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11971446Abstract: The invention discloses an interface system for an interconnected die and an MPU and a communication method thereof. The system comprises a data interface, an interrupt interface, and a debugging interface; the data interface comprises an SPI interface, a DDR data interface, and a DMA control interface; the interrupt interface is used for receiving an interrupt data packet from the network and parsing the interrupt data packet to obtain a pulse interrupt input required by the MPU; the debugging interface comprises a JTAG-Core debugging interface, which is used for receiving a debugging data packet from the network and translating the debugging data packet into a JTAG protocol for MPU debugging. The invention realizes the expansion of the master device MPU in the high-performance information processing microsystem and the high-speed communication between the master device and the interconnected dies.Type: GrantFiled: December 16, 2021Date of Patent: April 30, 2024Inventors: Jinghe Wei, Letian Huang, Zhiqiang Xiao, Mingang Feng, Taojie Ding, Lihua Zheng
-
Publication number: 20230060304Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: June 30, 2022Publication date: March 2, 2023Applicant: The U.S.A, as represented by the Secretary, Department of Health and Human ServiceInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20210324053Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: June 25, 2021Publication date: October 21, 2021Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20200231658Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: February 10, 2020Publication date: July 23, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20200054765Abstract: Provided herein are compositions comprising trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/AIDS.Type: ApplicationFiled: October 21, 2019Publication date: February 20, 2020Inventors: Zhi-Yong YANG, Gary J. NABEL, Ling XU, Ronnie WEI, Huawei QIU, Jochen BENINGA, Jochen KRUIP, Ercole RAO, Wulf Dirk LEUSCHNER, Christian BEIL, Christian LANGE, Mark CONNORS, John R. MASCOLA, Richard A. KOUP, Jinghe HUANG, Nicole A. DORIA-ROSE, Tongqing ZHOU, Peter D. KWONG, Young Do KWON, Amarendra PEGU, Mangaiarkarasi ASOKAN
-
Patent number: 10562960Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: March 18, 2016Date of Patent: February 18, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Publication number: 20190054182Abstract: Provided herein are compositions comprising trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, where in a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/AIDS.Type: ApplicationFiled: October 24, 2016Publication date: February 21, 2019Applicants: Sanofi, The USA, as Represented by the Secretary, Department of Health and Human ServicesInventors: Zhi-Yong YANG, Gary J. NABEL, Ling XU, Ronnie WEI, Huawei QIU, Jochen BENINGA, Jochen KRUIP, Ercole RAO, Wulf Dirk LEUSCHNER, Christian BEIL, Christian LANGE, Mark CONNORS, John R. MASCOLA, Richard A. KOUP, Jinghe HUANG, Nicole A. DORIA-ROSE, Tongqing ZHOU, Peter D. KWONG, Young Do KWON, Amarendra PEGU, Mangaiarkarasi ASOKAN
-
Publication number: 20180298083Abstract: Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: ApplicationFiled: March 18, 2016Publication date: October 18, 2018Applicant: The United States of America, as repsented By the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
-
Patent number: 10047148Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: GrantFiled: September 8, 2017Date of Patent: August 14, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
-
Patent number: 10047147Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: GrantFiled: August 4, 2014Date of Patent: August 14, 2018Assignee: The United States of American, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Leo Laub, John Mascola, Nancy Longo, Nicole Doria-Rose
-
Publication number: 20180002406Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: ApplicationFiled: September 8, 2017Publication date: January 4, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
-
Patent number: 9783595Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: GrantFiled: August 2, 2016Date of Patent: October 10, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
-
Publication number: 20160333076Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: ApplicationFiled: August 2, 2016Publication date: November 17, 2016Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
-
Patent number: 9475862Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: GrantFiled: November 7, 2012Date of Patent: October 25, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
-
Publication number: 20140348785Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: ApplicationFiled: November 7, 2012Publication date: November 27, 2014Inventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
-
Publication number: 20140342407Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Mark Connors, Jinghe Huang, Leo Laub, John Mascola, Nancy Longo, Nicole Doria-Rose, Marie Pancera